An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2017
At a glance
- Drugs CFZ 533 (Primary)
- Indications Graves' disease
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Jun 2017 Status changed from recruiting to completed.
- 14 Mar 2017 Planned End Date changed from 1 Apr 2017 to 2 May 2017.
- 14 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 2 May 2017.